Eisai

TOKYO, June 29, 2026 Eisai Co., Ltd. has announced it will present more than 50 scientific presentations highlighting the...

TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...

Tokyo & New York – March 27, 2026 Eisai and Nuvation Bio announced that the European Medicines Agency (EMA)...

Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...

Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...

TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...

TOKYO & STOCKHOLM — November 28, 2025. Eisai, in partnership with BioArctic, has submitted a New Drug Application (NDA)...

NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...